Andreas Budi WIJAYA, Furqan HIDAYATULLAH, Verina Veronica SETYABUDHI, Faizal Reza PAHLEVI, Rasyad INDRA, Tatit NURSETA

Profile of POT1 as telomerase shelterin component discriminates between cervical cancer and normal cervical cells

Background/aim: Telomerase activity is influenced by hTERT transcriptional regulation, shelterin, and posttranscriptional alternative splicing. Telomerase shelterin such as POT1 is highly correlated with various cancers. However, the profile of POT1 in cervical cancer has not been clearly identified. Therefore, it is important to identify its profile in cervical cancer biopsy tissue and normal cervical smears. Materials and methods: Biopsy tissue of cervical cancer patients and normal cervical smears were characterized using SDS-PAGE and western blot. Sixteen biopsy tissues of cervical cancer patients and 15 normal cervical smears were measured for POT1 level using ELISA. Results: The inline band at 70 kDa indicated that all samples had protein that was identified as POT1. Western blot showed that telomerase antibody only recognized POT1 in biopsy tissue of cervical cancer patients. There was a significant difference (P = 0.01) in POT1 level between biopsy tissue of cervical cancer patients and normal cervical smears. Conclusion: POT1 was identified at 70 kDa in biopsy tissue of cervical cancer patients and its level was higher than that in normal cervical smears. The high level of POT1 in the biopsy tissue of cervical cancer patients showed the influence of this shelterin component in cervical carcinogenesis and also cell immortalization.

PDF

___

1. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Fact Sheet: Genital HPV; 2010.
2. Forouzanfar MH, Lozano R, Lopez AD, Delossantos AM, Foreman KJ, Murray CJ. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011; 378: 1461-1484.
3. Catarino R, Araújo A, Coelho A, Gomes M, Nogueira A, Lopes C, Medeiros RM. Prognostic significance of telomerase polymorphism in non-small cell lung cancer. Clinical Cancer Research 2010; 16: 3706-3712.
4. Artandi SE, De Pinho RA. Telomeres and telomerase in cancer. Carcinogenesis 2010; 31: 9-18.
5. Zhen WS, Heng SJ, Wei Z, Qian JS, Ping WH, Sheng JY, Ping Q, Yi L, Mo L. Telomerase activity in cervical intraepithelial neoplasia. Chinese Medical Journal 2004; 117: 202-206.
6. Liddell, JE. Antibody Purification by Ammonium Sulfate Precipitation. University of Cardiff; 2003.
7. Wojtyla A, Gladych M, Rubis B. Human telomerase activity regulation. Mol Biol Rep 2011; 38: 3339-3349.
8. Ponsot E, Laguna AE, Delis AM, Kadi F. Telomere length and regulatory proteins in human skeletal muscle with and without ongoing regenerative cycles. Exp Physiol 2012; 55: 21-28.
9. Wanga F, Tanga M, Zeng Z, Wua R, Xue Y, Hao Y, Pang D, Zhao Y, Tana Z. Telomere- and telomerase-interacting protein that unfolds telomere G-quadruplex and promotes telomere extension in mammalian cells. Biochemistry 2012, PNAS Early Edition: 1-6.
10. Xin H, Liu D, Wan M, Safari A, Kim H, Sun W, OConnor MS, Songyang Z. TPP1 is a homologue of ciliate TEBP-beta and interacts with POT1 to recruit telomerase. Nature 2007; 445: 559-562.
11. Wang F, Podell ER, Zaug AJ, Yang Y, Baciu P, Cech TR, Lei M. The POT1-TPP1 telomere complex is a telomerase processivity factor. Nature 2007; 445: 506-510.
12. Liu F, Pu XY, Xiang GM, Jiang DN, Hou G, Huang DN. Expression of hPOT1 in HeLa cells and the probability of gene variation of hpot1 Exon14 in endometrial cancer are much higher than in other cancers. Asian Pacific J Cancer Prev 2012,
13: 5659-5663. 13. Fujii K, Sasahira T, Moriwaka Y. Protection of telomeres 1 protein levels are associated with telomere length in gastric cancer. Int J Mol Med 2008; 5: 599-604.
14. Wan SM, Tie J, Zhang YF. Silencing of the hPOT1 gene by RNA inference promotes apoptosis and inhibits proliferation and aggressive phenotype of gastric cancer cells, likely through upregulating PinX1 expression. J Clin Pathol 2011; 12: 1051-1057.
15. Tang T, Zhou FX, Lei H. Increased expression of telomererelated proteins correlates with resistance to radiation in human laryngeal cancer cell lines. Oncol Rep 2009; 6: 1505-1509.
16. Kondo T, Oue N, Yoshida K, Mitani Y, Naka K, Nakayama H, Yasui W. Expression of POT1 is associated with tumor stage and telomere length in gastric carcinoma. Cancer Research 2004; 64: 523-529.
17. Larssen SS, Fossberg E, Gaudernack G. Characterization of novel alternative splicing sites in human telomerase reverse transcriptase (hTERT): analysis of expression and mutual correlation in mRNA isoforms from normal and tumour tissues. BMC Molecular Biology 2006; 7: 26.
18. Bollmann FM. Physiological and pathological significance of human telomerase reverse transcriptase splice variants. Biochimie 2013; 95: 1965-1970.
19. Wong MS, Chen L, Foster C, Kainthla R, Shay JW, Wright WE. Regulation of telomerase alternative splicing: a target for chemotherapy. Cell Reports 2003; 3: 1028-1035.
20. Nagao K, Katsumata K, Aizawa Y, Saito N, Hirata H, Sasaki H, Yamamoto S, Hikiji K, Koiwa T, Hisatomi H. Differential alternative splicing expressions of telomerase reverse transcriptase in gastrointestinal cell lines. Oncol Rep 2004; 11: 127-131.